Nutcracker Therapeutics News Today

EMERYVILLE, Calif.--(BUSINESS WIRE)--Jan 8, 2024--

/PRNewswire/ -- The global biochips market size is estimated to grow by USD 43,273.01 million from 2022 to 2027, according to Technavio. The market is...

/PRNewswire/ -- The global biochips market size is estimated to grow by USD 43,273.01 million from 2022 to 2027, according to Technavio. The market is...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the appointment of Thomas J. Dietz, Ph.D., to the company’s board of directors.Dr. Dietz brings to Nutcracker T...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the upcoming poster presentation of new preclinical data for its lead therapeutic candidate, NTX-0250, which ta...

Capitalizing on the success of mRNA-based vaccines for COVID-19, Nutcracker is developing mRNA-based therapeutics with immunostimulatory properties.

ARCH Venture Partners led the Series C round of financing for Nutcracker Therapeutics, a company developing new RNA drugs. The company’s process for developing and manufacturing RNA therapies borrows from techniques used in the technology sector.

GEN’s new updated A-List of top companies in RNA-based biotech encompassing not only developers of vaccines and drugs based on various forms of RNA, but developers of RNA-based platform technologies.

GEN’s new updated A-List of top companies in RNA-based biotech encompassing not only developers of vaccines and drugs based on various forms of RNA, but developers of RNA-based platform technologies.